tirzepatide landrum sc Tirzepatide | Research Peptide |

Semaglutide, a GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management, has important effects on liver enzymes that clinicians and patients should understand

They may have the potential to cause bone loss

The paradigm shifted dramatically with the release of multi-society guidance in October 2024, endorsed by the ASA, American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, and Society of American Gastrointestinal and Endoscopic Surgeons [10]

Vision Changes: Some people with diabetes may see changes in their eyesight

ET: Federal comment period closed on FDA's proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list